Inozyme Pharma Inc. (INZY) Financial Statements (2024 and earlier)

Company Profile

Business Address 321 SUMMER STREET
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:188,600,000127,900,000111,800,000147,697,000
Cash and cash equivalents34,588,00032,915,00023,316,00028,040,000
Short-term investments154,001,00094,951,00088,485,000119,657,000
Other undisclosed cash, cash equivalents, and short-term investments11,00034,000(1,000) 
Receivables 385,000115,00062,000155,000
Prepaid expense 1,937,0002,015,0002,289,0002,323,000
Other undisclosed current assets5,328,0001,363,0001,191,000804,000
Total current assets:196,250,000131,393,000115,342,000150,979,000
Noncurrent Assets
Operating lease, right-of-use asset1,126,0001,620,0002,053,000 
Property, plant and equipment1,466,0002,018,0002,383,0002,648,000
Long-term investments and receivables    12,199,000
Long-term investments    12,199,000
Prepaid expense 1,694,0003,810,0003,409,0003,183,000
Restricted cash and investments311,000 354,000354,000
Other noncurrent assets  354,000  
Total noncurrent assets:4,597,0007,802,0008,199,00018,384,000
TOTAL ASSETS:200,847,000139,195,000123,541,000169,363,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,776,00013,899,00010,902,0009,973,000
Accounts payable1,166,0002,544,0002,394,0003,069,000
Accrued liabilities12,610,00011,355,0008,508,0006,904,000
Other undisclosed current liabilities910,000816,000731,000 
Total current liabilities:14,686,00014,715,00011,633,0009,973,000
Noncurrent Liabilities
Long-term debt and lease obligation:   2,640,000 
Liabilities, other than long-term debt913,0001,947,000  
Other liabilities  124,000  
Operating lease, liability913,0001,823,0002,640,000 
Other undisclosed noncurrent liabilities44,769,0004,139,000(2,640,000)1,287,000
Total noncurrent liabilities:45,682,0006,086,0002,640,0001,287,000
Total liabilities:60,368,00020,801,00014,273,00011,260,000
Equity
Equity, attributable to parent140,479,000118,394,000109,268,000158,103,000
Common stock6,0004,0002,0002,000
Additional paid in capital426,362,000333,356,000256,948,000249,175,000
Accumulated other comprehensive income (loss)41,000(205,000)18,0002,000
Accumulated deficit(285,930,000)(214,761,000)(147,700,000)(91,076,000)
Total equity:140,479,000118,394,000109,268,000158,103,000
TOTAL LIABILITIES AND EQUITY:200,847,000139,195,000123,541,000169,363,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(75,645,000)(68,675,000)(56,646,000)(57,041,000)
Operating loss:(75,645,000)(68,675,000)(56,646,000)(57,041,000)
Nonoperating income4,476,0001,614,00022,000617,000
Investment income, nonoperating7,837,0001,933,000211,000370,000
Other nonoperating income (expense)(28,000)(319,000)(189,000)247,000
Interest and debt expense(3,333,000)   
Other undisclosed loss from continuing operations before equity method investments, income taxes    
Loss from continuing operations:(74,502,000)(67,061,000)(56,624,000)(56,424,000)
Loss before gain (loss) on sale of properties:(56,624,000)(56,424,000)
Other undisclosed net income3,333,000   
Net loss available to common stockholders, diluted:(71,169,000)(67,061,000)(56,624,000)(56,424,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(71,169,000)(67,061,000)(56,624,000)(56,424,000)
Other comprehensive income (loss)246,000(223,000)16,000(3,000)
Comprehensive loss, net of tax, attributable to parent:(70,923,000)(67,284,000)(56,608,000)(56,427,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: